A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects

INTRODUCTION: Iberdomide, a novel cereblon modulator (CELMoD(®)), is currently under clinical investigation for hematology indications. To evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of iberdomide and its major active metabolite M12, a phase 1, multicenter, open-label s...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yiming, Ye, Ying, Gaudy, Allison, Ghosh, Atalanta, Xue, Yongjun, Wang, Alice, Zhou, Simon, Li, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985425/
https://www.ncbi.nlm.nih.gov/pubmed/36880014
http://dx.doi.org/10.2147/CPAA.S397826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985425/
https://www.ncbi.nlm.nih.gov/pubmed/36880014
http://dx.doi.org/10.2147/CPAA.S397826

Ejemplares similares